# Harrow, Inc. (HROW) Stock Analysis: Navigating the Eye-Care Market with a Potential 123% Upside

- Link: https://www.directorstalkinterviews.com/harrow-inc-hrow-stock-analysis-navigating-the-eye-care-market-with-a-potential-123-upside/4121266276
- Published: 2026-10-13T10:14:39+01:00
- Author: Madison Wilson

Harrow, Inc. (NASDAQ: HROW) is capturing the attention of investors within the healthcare
sector, particularly in the specialty and generic drug manufacturing industry. With
a market capitalization of $1.09 billion, Harrow is carving out a niche in the ophthalmic
pharmaceutical market in the United States, offering a range of specialized products
through its Branded and ImprimisRx segments.

Despite its current share price of $29.11, Harrow presents an enticing opportunity
for investors, with a potential upside of 123.29% based on an average target price
of $65.00. The stock’s 52-week range has seen it fluctuate between $29.03 and $54.80,
indicating significant volatility but also potential for growth.

Harrow’s forward P/E ratio of 10.50 suggests expectations of profitability, although
its trailing P/E ratio and other valuation metrics are currently unavailable. The
company’s revenue growth of 10.90% is a positive signal, yet investors should note
the negative earnings per share (EPS) of -0.99 and a return on equity (ROE) of -
116.07%, reflecting challenges in profitability. Furthermore, Harrow’s free cash
flow stands at -$5,490,125, highlighting the need for prudent financial management.

The company’s diverse product portfolio is a key strength, featuring ophthalmic 
solutions such as IHEEZO and IOPIDINE, as well as biosimilars like BYOOVIZ. These
products position Harrow well within the competitive eye-care market, targeting 
conditions like age-related macular degeneration and diabetic retinopathy.

Analysts remain optimistic, with nine buy ratings and no hold or sell recommendations,
reinforcing confidence in Harrow’s strategic direction. The target price range of
$45.00 to $88.00 underscores the potential for significant appreciation, especially
as the company continues to innovate and expand its market presence.

From a technical perspective, Harrow’s 50-day and 200-day moving averages are $36.10
and $39.86, respectively, suggesting the stock is currently trading below these 
averages. The Relative Strength Index (RSI) of 46.17 indicates the stock is neither
overbought nor oversold, providing a neutral technical signal. However, the MACD
and signal line are both negative, which could suggest potential bearish momentum.

Harrow, Inc.’s recent name change from Harrow Health, Inc. reflects its focused 
commitment to the ophthalmic pharmaceutical sector. Founded in 1998 and headquartered
in Nashville, Tennessee, the company has a solid foundation and a promising pipeline
that could drive future growth.

For investors considering an entry into the healthcare sector, Harrow offers a compelling
narrative of both challenges and opportunities. As the company navigates its financial
hurdles and capitalizes on its robust product offerings, it stands as a potential
growth story worth watching in the coming quarters.

Share on:
